Brickl R, Schmid J, Koss F W
Natl Cancer Inst Monogr. 1984 Dec;66:63-7.
We discovered a strong but saturable first-pass effect after oral administration of psoralens by using different doses and simultaneous or timed application of stable isotopes. Therefore, small variations of dose, disintegration of drug, and amount and rate of absorption gave rise to great differences in plasma levels and therapeutic efficacy. For practical therapy, the following conclusions can be drawn: 1) Galenical forms of psoralens should ensure a quick and highly reproducible absorption. 2) In the event that inefficacy has been detected, plasma levels should be determined, and the psoralen dosage should be increased rather than the irradiation doses in most instances. 3) For oral psoralen and 320- to 400-nm UV (UVA) treatment, a combination of 5-methoxypsoralen (5-MOP) and 8-MOP (with a lower dose and either administered 30 minutes later than the 5-MOP or in a drug product with quick release of 5-MOP and quick but delayed release of 8-MOP) results in much higher efficacy and reproducibility. Therefore, compared with the single drug, in the combination, dose of drug and the amount of irradiation can be reduced considerably which may result in increased safety. 4) Plasma levels after oral administration of dissolved 4,5',8-trimethylpsoralen are low, but phototoxicity is comparable to that of the 5-MOP and 8-MOP.
我们通过使用不同剂量以及同时或定时应用稳定同位素,发现口服补骨脂素后存在强烈但可饱和的首过效应。因此,剂量的微小变化、药物崩解以及吸收量和吸收率会导致血浆水平和治疗效果出现很大差异。对于实际治疗,可得出以下结论:1)补骨脂素的药剂形式应确保快速且高度可重复的吸收。2)如果检测到无效,应测定血浆水平,并且在大多数情况下应增加补骨脂素剂量而非照射剂量。3)对于口服补骨脂素和320至400纳米紫外线(UVA)治疗,5-甲氧基补骨脂素(5-MOP)和8-MOP联合使用(5-MOP剂量较低,且比5-MOP晚30分钟给药,或者制成5-MOP快速释放、8-MOP快速但延迟释放的药物制剂)可产生更高的疗效和可重复性。因此,与单一药物相比,联合使用时药物剂量和照射量可大幅降低,这可能会提高安全性。4)口服溶解的4,5',8-三甲基补骨脂素后的血浆水平较低,但其光毒性与5-MOP和8-MOP相当。